DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/j8k3vv/metastatic) has announced the addition of the "Metastatic Prostate Cancer - Pipeline Review, H2 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for Metastatic Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Prostate Cancer and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies Involved in Therapeutics Development
- Actinium Pharmaceuticals, Inc.
- Camurus AB
- Dongkook Pharmaceutical Co., Ltd.
- Eli Lilly and Company
- EntreChem, S.L.
- Johnson & Johnson
- MedImmune, LLC
- MEI Pharma, Inc.
- Merck & Co., Inc.
- OXiGENE, Inc.
- Progenics Pharmaceuticals, Inc.
- ValiRx Plc
- abiraterone acetate
- Cell Therapy to Target PSMA for Metastatic Prostate Cancer
- leuprolide acetate
- Recombinant Protein for Oncology
- triptorelin pamoate
- Vaccine For Oncolytic Newcastle Disease Virus
For more information visit http://www.researchandmarkets.com/research/j8k3vv/metastatic